Dicerna Pharmaceuticals, Inc., A Novo Nordisk Company

This study is testing an investigational drug called DCR-PHXC in children under 6 years old who have a rare, inherited disease called Primary Hyperoxaluria Type 1 (PH1). PH1 causes kidney damage and often leads to kidney failure, requiring dialysis or transplant. The main goals a…

This is the first human study testing a new cancer drug called DCR-PDL1, given through an IV. Researchers will enroll 32 adults with advanced solid tumors that haven't responded to standard treatments. The main goal is to find the safest dose by testing four different levels and …